News release from Pharma& – MHRA approval of Pegasys for ET & PV patients

MHRA approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a treatment for eligible patients with the myeloproliferative neoplasms (MPNs) blood cancers polycythaemia vera (PV) and essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment for adults with essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment…